Key points are not available for this paper at this time.
Background The therapeutic value of neoadjuvant chemotherapy (NAC) for locally advanced esophageal squamous cell carcinoma (ESCC) remains uncertain compared to surgery alone (SA), particularly in real-world settings. This study utilized propensity score matching (PSM) to compare survival outcomes between NAC and surgery in a well-balanced ESCC cohort, while assessing pathological complete response (pCR) and prognostic factors to guide clinical decision-making. Methods The study conducted a retrospective analysis of 690 patients with locally advanced ESCC (T3-4aN0-3M0) who underwent radical esophagectomy between 2009 and 2019. PSM was employed to balance baseline characteristics, yielding 452 matched patients (135 NAC, 317 SA). NAC consisted of platinum-based doublet regimens. Survival outcomes, including disease-free survival (DFS) and overall survival (OS), were analyzed using Kaplan-Meier and Cox regression methods. pCR were assessed using CAP criteria. Results NAC significantly improved 5-year DFS (28.7% vs. 18.5%, P = 0.001) and OS (37.9% vs. 24.2%, P = 0.001) compared to SA. Patients achieving pCR (11.9%) exhibited superior DFS (5-year: 55.0% vs. 18.5%, P = 0.010) and OS (5-year: 59.8% vs. 35.0%, P = 0.019). Multivariate analysis identified NAC, histologic grade, ypN stage, vessel/nerve invasion, and pCR as independent prognostic factors. Conclusions This real-world data supports that NAC significantly improves survival outcomes compared to SA in locally advanced ESCC. pCR post-NAC independently predicted improved OS.
Wang et al. (Mon,) studied this question.